Looking for an alternative to semaglutide? Here's what actually exists

The common misconception: semaglutide and its alternatives all work the same way

Many people searching for an alternative to semaglutide assume all weight-loss injections are essentially interchangeable, different brands, same effect. That's not quite right. Semaglutide activates the GLP-1 receptor, one pathway involved in appetite regulation and gastric emptying. Tirzepatide, marketed in the UK as Mounjaro, activates both the GLP-1 receptor and a second receptor called GIP. Because GIP and GLP-1 pathways interact differently, the two medicines produce distinct physiological effects, not just a stronger or weaker version of the same signal.

This matters in practice. In the SURMOUNT-5 open-label trial published in the New England Journal of Medicine in 2025, adults with obesity who took tirzepatide lost more weight on average over 72 weeks than those on semaglutide 2.4mg. That's a real clinical difference, not a marketing claim. NICE acknowledged indirect comparisons favouring tirzepatide in its appraisal of tirzepatide published as TA1026 in December 2024.

The point here isn't that one is definitively better for any individual. It's that these are genuinely different medicines, and which one a prescriber recommends will depend on your health history, other medicines you take, and how your body responds. Expecting them to behave identically is the misconception worth correcting first.

Tirzepatide as an alternative: what you need to know before asking for it

Tirzepatide (Mounjaro) is licensed in the UK for adults with a BMI of 30 or above, or 27 and above with at least one weight-related condition such as high blood pressure, raised cholesterol, type 2 diabetes or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. You can read a full overview of semaglutide and how it compares if you want the clinical detail side by side.

Treatment starts at 2.5mg (a dose whose job is to let your system adjust, not to produce rapid weight loss immediately) and is titrated by your prescriber in four-week steps up to 15mg. Common side effects are GI-led: nausea, loose stools, constipation and indigestion are the most frequently reported, usually settling within the first few weeks of each new dose. These are similar in character to semaglutide's side-effect profile, though individual tolerance varies considerably.

If you're already on semaglutide and considering switching, that's a conversation for your prescriber. Evidence of your current dose and a clinical re-assessment would both be part of that process. It's not simply a case of swapping one pen for another.

What about the new oral option, is a semaglutide tablet a genuine alternative to the injection?

For people who dislike injections, the MHRA approved Wegovy tablets in June 2026, the first oral GLP-1 medicine licensed for weight management in the UK. You can find a full breakdown on the Wegovy page, but the headline facts are these: it reaches a maintenance dose of 25mg daily, taken first thing in the morning on an empty stomach with a small amount of plain water, at least 30 minutes before food or other medicines, and if you're wondering whether there is a best time of day to take Wegovy, that timing guidance is worth reading before you start. No refrigeration is needed, which some people find more convenient than storing a pen in the fridge.

Phase 3 trial data showed around 13.6% average weight loss at 64 weeks, rising to about 17% among participants who adhered fully to the treatment schedule. That's somewhat lower than the injection's results at 2.4mg weekly, and lower again than tirzepatide 15mg. So the oral route is a genuine option, but not a like-for-like swap on efficacy. Whether that trade-off makes sense depends on the individual. You might also want to look at whether any weight-loss alternative is available without prescription in the UK, the short answer is that nothing in the same class is.

Choosing between options: what a clinical assessment actually covers

If you're weighing these medicines against each other, the question of cost will almost certainly come up. Treatment prices vary by dose, provider, and what's included, a price comparison across UK options can help you understand the market context before you commit to anything. Price alone is a poor guide for prescription medicines, but it's a reasonable thing to understand upfront.

Beyond cost, a prescriber will look at your BMI, any weight-related conditions, your medication list (oral contraceptives in particular have an interaction note with tirzepatide that's worth knowing about), and whether you've used these medicines before. Some people also notice unexpected changes to their food preferences during treatment, and there is useful information on whether Wegovy alters taste if that is something you want to understand before starting. Both semaglutide and tirzepatide are Black Triangle medicines, meaning they carry additional MHRA monitoring requirements; the NHS tirzepatide medicines page covers the main safety points in accessible language.

At nume, a GPhC-registered Independent Prescriber reads every consultation personally on the same day it's submitted. If you order before midday on a working day and are clinically approved, your treatment is dispatched that afternoon and arrives via DPD the next working day in plain, unbranded packaging, tracking on your phone, nothing identifying on the box itself. To find out which option fits your situation, check your eligibility with a free consultation.